Skip to main content
. 2023 Feb 25;14:1098. doi: 10.1038/s41467-023-36681-z

Fig. 4. Gonadotrope activation or FSH administration is sufficient to improve metabolic disorders including hepatic steatosis in female mice.

Fig. 4

a Representative images of pituitaries from PBS (left) and clozapine-N-oxide (right) i.p. injected GRIC/eR26-DREADD mice. The expression of cFos (shown in green) was used as a marker for cellular activation. Gonadotropes are shown in red, corresponding to the expression of LH and FSH. DAPI is shown in blue (scale bars = 50 μm in full-size images, 20 μm in insets, and filled arrowheads indicate activated gonadotropes.). b Body weight, c glucose tolerance, d liver oil red O staining quantification, and e representative images (scale bars = 100 μm, filled arrowheads indicate lipid droplets) in clozapine-N-oxide (CNO) treated Cre+ (chemogenetically-activated) and Cre− (control) gonadectomized mice on a high-fat diet (HFD). f Plasma FSH levels from CNO-injected Cre+ (chemogenetically activated) and Cre− (control) OVX mice on HFD. g Body weight, h glucose tolerance, and i liver oil red O staining quantification in FSH-treated and saline-treated OVX mice on HFD. Error bars represent standard error mean. * = P < 0.05, ** = P < 0.01 and *** = P < 0.001. For statistical details, including individual P-values, see Supplementary Data 1. Source data are provided as a Source Data file.